Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of Topiramate in epilepsy patients

被引:72
作者
Kockelmann, E [1 ]
Elger, CE [1 ]
Hehnstaedter, C [1 ]
机构
[1] Univ Bonn, Dept Epileptol, D-53105 Bonn, Germany
关键词
epilepsy; Topiramate; withdrawal; cognition; frontal lobe; adverse effects;
D O I
10.1016/S0920-1211(03)00078-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Rationale: Topiramate (TPM) is a highly effective anticonvulsant drug, but a comparably high rate of cognitive adverse effects have been reported. In this study, we investigated changes in frontal lobe associated cognitive measures after TPM withdrawal in epilepsy patients hospitalized for presurgical evaluation. Methods: Twenty epilepsy patients were administered a brief neuropsychological test battery before and after withdrawal of TPM. Neuropsychological evaluation included a verbal fluency task, verbal (Wechsler's digits) and spatial spans (Corsi block-tapping) and Trail Making Test (TMT, parts A and B). Median baseline dosage of TPM was 237.5 mg/d, the median retest-interval was 8 days. Results were compared to a matched group of patients, who had been tested and retested before and after reduction of AEDs other than TPM at comparable time intervals. Results: After TPM withdrawal, group performance appeared significantly improved in five of six tests administered. The scores of the control patients remained largely unchanged after drug reduction. After withdrawal, the scores of the TPM group did not differ significantly from the results of the control group whereas pronounced differences had been observed before. Individual improvement became apparent in the majority of patients. Cognitive performance was not correlated to current daily dosages/current blood serum levels of TPM. Conclusion: Withdrawal of TPM causes significant improvement in frontal lobe associated measures like verbal fluency and working memory. As withdrawal was part of the preoperative work-up, and not initiated because of patients' complaints or hints of intoxication, cognitive impairment due to TPM appears to be easily overlooked and underestimated. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:171 / 178
页数:8
相关论文
共 25 条
[1]   A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures [J].
Aldenkamp, AP ;
Baker, G ;
Mulder, OG ;
Chadwick, D ;
Cooper, P ;
Doelman, J ;
Duncan, R ;
Gassmann-Mayer, C ;
de Haan, GJ ;
Hughson, C ;
Hulsman, J ;
Overweg, J ;
Pledger, G ;
Rentmeester, TW ;
Riaz, H ;
Wroe, S .
EPILEPSIA, 2000, 41 (09) :1167-1178
[2]  
[Anonymous], 1989, MEHRFACHWAHL WORTSCH
[3]   Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures [J].
BenMenachem, E ;
Henriksen, O ;
Dam, M ;
Mikkelsen, M ;
Schmidt, D ;
Reid, S ;
Reife, R ;
Kramer, L ;
Pledger, G ;
Karim, R .
EPILEPSIA, 1996, 37 (06) :539-543
[4]   Effect of topiramate on attention [J].
Burton, LA ;
Harden, C .
EPILEPSY RESEARCH, 1997, 27 (01) :29-32
[5]  
CORSI PM, 1972, DISS ABSTR INT, V34, p819B, DOI DOI 10.1016/B978-0-12-564350-4.50011-7
[6]   Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages [J].
Faught, E ;
Wilder, BJ ;
Ramsay, RE ;
Reife, RA ;
Kramer, LD ;
Pledger, GW ;
Karim, RM ;
Barr, A ;
Fischer, J ;
Bergen, D ;
Boor, D ;
Browne, T ;
Davenport, J ;
Dichter, M ;
Drake, M ;
Kuzniecky, R ;
Mamdani, M ;
McCutchen, C ;
Naritoku, D ;
Potolicchio, S ;
Ramani, V ;
Ramsay, R ;
Shinnar, S ;
So, E ;
Wilder, B .
NEUROLOGY, 1996, 46 (06) :1684-1690
[7]  
Faught E, 1997, NEUROLOGY, V48, P43006
[8]   Empirical techniques for determining the reliability, magnitude, and pattern of neuropsychological change after epilepsy surgery [J].
Hermann, BP ;
Seidenberg, M ;
Schoenfeld, J ;
Peterson, J ;
Leveroni, C ;
Wyler, AR .
EPILEPSIA, 1996, 37 (10) :942-950
[9]  
HORN W, 1983, LEISTUNGS PRUF SYSTE
[10]   Cognitive impairment in add-on therapy with topiramate [J].
Huppertz, HJ ;
Quiske, A ;
Schulze-Bonhage, A .
NERVENARZT, 2001, 72 (04) :275-+